Agilent Technologies shares climbed roughly 18.4% in mid-day trading following a fiscal second-quarter report that outperformed analyst forecasts across major measures and prompted the company to lift its outlook for the full fiscal year.
For the quarter ended April 30, 2026, Agilent recorded revenue of $1.83 billion, a 10.0% increase on a reported basis and a 6.3% rise on a core basis compared with the same period last year. Non-GAAP earnings per share were $1.49, up 14% year-over-year, topping the analyst consensus of $1.41 and exceeding the high end of Agilent’s own guidance range.
Following the results, management tightened its guidance for fiscal 2026, raising expected revenue to a range of $7.39 billion to $7.49 billion and boosting full-year non-GAAP EPS guidance to $6.00 to $6.10, which represents 7% to 9% growth from the prior year.
Why the stock moved
The combination of a meaningful earnings beat, an upward guidance revision and a series of positive analyst moves created a stacked set of catalysts that drove the sizable share-price move. Such a move is notable for Agilent; the company had recorded only four single-day moves larger than 5% over the prior year, indicating that today’s news materially altered investor perceptions of the business.
On the company’s earnings call, CEO Padraig McDonnell characterized the instrument replacement cycle as providing a "200-300 basis point tailwind" to liquid chromatography growth. Management emphasized that the benefit is not purely from equipment replacement but also from winning share in competitive accounts. McDonnell additionally identified the GLP-1 drug wave as a structural tailwind, noting Agilent’s instruments are used in quality assurance, quality control and development labs at pharmaceutical customers scaling production.
Street response
Wall Street reacted quickly. BofA Securities upgraded Agilent to Buy from Neutral and set a $145 price target, with analyst Michael Ryskin pointing to ongoing strength in LC and GC replacement cycles that he said remain in early innings. Stifel reiterated its Buy rating and maintained a $170 price target, highlighting that Agilent exceeded expectations despite current macroeconomic conditions. Leerink raised its price target to $170 from $165, kept an Outperform rating and cited roughly 6% organic growth in the quarter versus consensus estimates of 5%.
Market backdrop and segment performance
The broader market offered modest support for the rally. The S&P 500 was up about 0.6% and the Nasdaq advanced near 0.95%, with both trading close to all-time highs, while the Dow Jones Industrial Average was essentially flat. The broader indices received some support from a report that negotiators reached a deal to extend an Iran ceasefire, with the S&P 500 and Nasdaq posting fresh intraday highs.
Not all Agilent regions and segments performed uniformly. Revenue from China declined 9% in the quarter, a shortfall management attributed to funding delays and tighter government spending. The Academia and Government segment also slipped about 5% amid uncertainty around multiyear grant funding.
Strategic context
Beyond the quarter, investors also factored in Agilent’s pending acquisition of Biocare Medical. The $950 million all-cash deal, expected to close by the fourth quarter of fiscal 2026, is projected to be accretive to EPS roughly 12 months after closing. That anticipated accretion adds a longer-term strategic dimension to the near-term financial momentum.
Outlook and implications
The results and guidance raise underscore accelerating demand dynamics in key instrument categories and the potential for continued share gains in competitive replacement cycles. Analysts highlighted the early-stage nature of replacement-driven growth and flagged the GLP-1–related demand backdrop as a structural positive for instrument placements in pharma labs focused on QA/QC and scale-up.
However, pockets of weakness in China and softness in the Academia and Government segment underscore that regional and customer-type variability remains a factor for near-term revenue trends.